

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re U.S. Patent 6,525,060

HARDERN et al.

Atty. Ref.: 3764-205; Confirmation No. 2221

Appl. No. 09/508,195

TC/A.U. 1624; Issued: February 25, 2003

Filed: March 8, 2000

Examiner: Ford, J.M.

For: TRIAZOLO(4,5-D)PYRIMIDINE COMPOUNDS

* * * * *

Mail Stop Hatch-Waxman PTE
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

POWER OF ATTORNEY

AstraZeneca UK Limited, the assignee of the entire legal right, title and interest in US Patent 6,525,060, hereby appoints the attorneys of **Customer Number 23117** individually and collectively its agent to prosecute the present application for patent term extension, and to transact all business in the Patent and Trademark Office in connection therewith.

Please direct correspondence for this application to the address associated with **Customer Number 23117**. Please direct telephone calls to Leonard C. Mitchard at (703) 816-4005.

Certificate Under 37 C.F.R. §3.73(b)

AstraZeneca UK Limited, a corporation having a place of business at 2 Kingdom Street, London UK W2 6BD, hereby states that it is the assignee of the entire legal right, title and interest in the patent identified above by virtue of an assignment from the inventors to the aforesaid assignee recorded at the United States Patent Office on March 8, 2000 at reel 011067, frame 0015.

The undersigned (whose title is typed below) is empowered to sign this statement on behalf of the assignee.

AstraZeneca UK Limited

07-SEPTEMBER-2011

Date

By:



Name: DR ALLEN F GILES

Title: AUTHORISED REPRESENTATIVE